A word from the President
The aim of this site is to inform you of all the activities we undertake as healthcare professionals.
Our role as entrepreneurs is to conceive, develop and implement a line of activity in a constantly and rapidly changing world. In this environment, we aim to provide the most appropriate solution to meet any challenge facing us.
It is only by being innovative, seeing these phenomena differently, and coming up with creative ideas that we can change our methods and adopt an appropriate attitude and behaviour which can help us to adjust to new situations.
By thinking this way and constantly questioning ourselves, we, and all the Eumedica team, set our course in the world of industry.
Jacques MERCKX
President C.E.O.
Mission and values
Our company's development is founded on:
- Supplying physicians and pharmacists with medicinal products which have undeniable therapeutic indications so that patients have continuity of care.
- Marketing new products which adhere to the health policy the authorities are endeavouring to establish, namely, not trying to cover very broad markets, but instead, targeting serious diseases for which a medicinal product is critical.
- Developing new drugs and re-evaluating old essential drugs so that patients are guaranteed the best treatment.
- Highly selective administration in antibiotic treatment, to maintain long-term efficacy (problematic of resistance).
- Working with academics to set up an international research unit for medicinal products targeting serious conditions in the hospital environment.
Information about the group
The Group is present in Belgium, France, United Kingdom, Switzerland, Italy and Austria, and currently employs over 80 people.
A few recent dates
| 2010 |
- Launch of the TEA study (temocillin) in the United Kingdom
|
| 2009 | - Eumedica moves in its new offices in Manage
- Publication of new data about temocillin
- Journal of Antimicrobial Chemotherapy 2009 63(2):243-245.
- 2008 "Prescrire" award for the new indication for Actosolv® for Eumedica
- Acquisition of Somatostatin-UCB® world-wide
|
| 2008 | - Extension of the capacity of the distribution centre by 1250m² resulting in a total of 4000m²
- Construction of a new administrative and research centre in Manage
- Publication of new data about temocillin
- Journal of Cystic Fibrosis 2008 7(6):551-4.
|
| 2007 | - Another international top 10 multinational hands over distribution of its clinical trial products to Eumedica
- Publication of new in vitro data about temocillin
- European Journal of Clinical Microbiology & Infectious Diseases 2007, vol. 26, no11, pp. 777-783.
- Scientific publication in collaboration with the Université Catholique de Louvain
- Bioorganic & Medicinal Chemistry Letters. 2007, vol. 17, no21, pp. 5758-5762
- Publication of new data about temocillin breakpoints in United Kingdom
- Journal of Antimicrobial Chemotherapy 2007 Jul;60(1):185-7.
|
| 2006 | - Launch of Negaban® in the United Kingdom
- New indication for Actosolv® 100.000 in France and in Belgium
- Launch of Somatostatine-Eumedica® in Belgium
- Publication of new data about temocillin
- Journal of Cystic Fibrosis, Volume 5, Issue 2, Pages 121-124.
- Journal of Antimicrobial Chemotherapy 2006, vol.57, no5, pp.1012-1014.
|
| 2004 | - Temocillin is designated Orphan Drug in Europe (EMEA) and the United States (FDA)
- Launch of Actosolv® in France
|
| 2003 | - Eumedica moves in its new distribution centre in Manage
|
| 2002 | - Eumedica sells its range of ophthalmological products to Théa
- Acquisition of Dopram®, Robinul® and Robinul Neostigmine® from American Home Products (AHP)
- Acquisition of Actosolv® from Aventis for Belux
- Acquisition of Pre-Par® from Solvay Pharma for Belux
- One of the largest pharmaceutical multinationals chooses Eumedica to distribute their clinical trial products throughout Europe
|
| 2001 | - Publication of new data about temocillin
- Acta Clin Belg 2001 Nov-Dec;56(6):354-9.
|
